MANCO Project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003651

The MANCO consortium has reached an important milestone!

The MANCO team has been searching for broadly neutralizing human monoclonal antibodies to treat COVID-19. We identified a broadly reactive SARS-CoV-2 – 87G7 – that potently neutralized Omicron and other variants of concern. Moreover we demonstrated that 87G7 can provide protection against infection with these SARS-CoV-2 variants in animal models. This is a huge step for the MANCO project!

The 87G7 antibody has been published in the journal Science Immunology.

Logo_ManCo2

MANCO Project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003651